Frontlight ResearchEarly access
CompletedPhase 2/3
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Key facts
- Who runs it
- Pfizer
- Where
- Atlanta, Augusta, Austin, Boston, Charlotte, Chicago, Cincinnati, Hackensack, Hartford, Houston, Indianapolis, Lake Success, Little Rock, Loma Linda, Los Angeles, Miami, Minneapolis, New York, Philadelphia, Portland, Salt Lake City, San Bernardino, San Diego, Seattle, The Bronx, and Washington D.C., United StatesSee the 43 sitesAlso in 18 other countries, 60 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 302 people enrolled
- Started
- 18 Mar 2013
- Ended
- 12 Feb 2025
- Type of study
- Interventional
- Treatments tested
- Tofacitinib
- Record updated
- 23 March 2026
Who can take part
- Age
- 2 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Pediatric subjects with JIA aged from 2 to less than 18 years who met entry criteria for the qualifying/index study and in the opinion of the investigator have sufficient evidence of JIA disease activity to warrant use of tofacitinib as a DMARD. Subjects turning 18 years of age during participation in the qualifying/index study or subsequently will be eligible for participation in this study
- The subject has discontinued disallowed concomitant medications for the required time prior to the first dose of study drug, as defined in Appendix 1, and is taking only those concomitant medications in doses and frequency allowed by the protocol
- Fertile male subjects and female subjects of childbearing potential who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must be using a highly effective method of contraception as outlined in this protocol throughout the study and for at least 28 days after the last dose of study medication
- Subjects must have previously completed participation in a qualifying study of tofacitinib for the treatment of JIA. Subjects who have required earlier discontinuation of treatment in a qualifying study for reasons other than tofacitinib related serious adverse events may be eligible
Who cannot take part
- Infections:; Chronic infections; Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 3 months prior to the first dose of study drug; Any treated infections within 2 weeks of baseline visit; A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus; History of infected joint prosthesis with prosthesis still in situ
- History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex
- persistent oligoarthritis, and undifferentiated JIA
Where in United States
Also in 18 other countries, 60 sites
- Center for Advanced PediatricsAtlanta, United States
- AU Medical CenterAugusta, United States
- Augusta UniversityAugusta, United States
- Dell Children's Medical Group, Dell Children's Medical CenterAustin, United States
- Tufts Medical Center - Floating Hospital for ChildrenBoston, United States
- Atrium Health- Investigational Drug ServicesCharlotte, United States
- Levine Children's Specialty CenterCharlotte, United States
- Pediatric ResearchCharlotte, United States
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
- The University of Chicago Medical CenterChicago, United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United States
- Hackensack University Medical CenterHackensack, United States
- Connecticut Children's Medical CenterHartford, United States
- Texas Children's Hospital - Investigational PharmacyHouston, United States
- Texas Children's Hospital - Main HospitalHouston, United States
- Texas Children's Hospital- Clinical Care CenterHouston, United States
- Texas Children's Hospital- Clinical Research CenterHouston, United States
- Texas Children's Hospital/Baylor College of Medicine- Feigin CenterHouston, United States
- Riley Hospital for Children at IU HealthIndianapolis, United States
- Cohen Children's Medical Center of New YorkLake Success, United States
- Arkansas Children's HospitalLittle Rock, United States
- Loma Linda University Children's HospitalLoma Linda, United States
- Loma Linda University Clinical Trials CenterLoma Linda, United States
- Loma Linda University Eye InstituteLoma Linda, United States
- Loma Linda University General Pediatric Clinic - MeridianLoma Linda, United States
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology)Loma Linda, United States
- Children's Hospital Los AngelesLos Angeles, United States
- Nicklaus Children's HospitalMiami, United States
- Explorer Clinic, University of Minnesota Children's HospitalMinneapolis, United States
- Columbia University Medical Center-Herbert Irving PavillionNew York, United States
- The Children's Hospital Of PhiladelphiaPhiladelphia, United States
- Randall Children's Hospital at Legacy EmanuelPortland, United States
- Intermountain - Primary Children's HospitalSalt Lake City, United States
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology)San Bernardino, United States
- Rady Children's Hospital - San DiegoSan Diego, United States
- Rady Children's Hospital Center for Pediatric Clinical ResearchSan Diego, United States
- Rady Children's Hospital Rheumatology ClinicSan Diego, United States
- Rady Children's Hospital San Diego- Education and Office BuildingSan Diego, United States
- Rady Children's Research PharmacySan Diego, United States
- Seattle Children's HospitalSeattle, United States
- Montefiore Medical CenterThe Bronx, United States
- Children's National Medical CenterWashington D.C., United States
- IDS PharmacyWashington D.C., United States
About the trial
What the trial wants to find out
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
The group in the trial
- TofacitinibTreatment being tested
All patients will be in tofacitinib treatment group.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
- Publications
- Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.Arthritis & rheumatology (Hoboken, N.J.), 2026
- Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.Annals of the rheumatic diseases, 2024
- Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis.CPT: pharmacometrics & systems pharmacology, 2024
- Record updated
- 23 March 2026